European Health Data & Evidence Network
(Temporary website)

Today, in Europe, we are challenged to generate insights and evidence from real world clinical data at scale, to support patients, clinicians, payers, regulators, governments, and the pharmaceutical industry in understanding wellbeing, disease, treatments, outcomes and new therapeutics and devices. Unfortunately, such data is difficult to use at scale, in a myriad of languages, systems and structures, with challenging policy restrictions and technology considerations. Consequently, using real world data for research, reflective of what happens for patients in their own experience of healthcare, is very challenging.

The Electronic Health Data in a European Network (EHDEN) consortium will provide the infrastructure and eco-system to make this ambition come true.

The main objectives of the EHDEN Consortium are:

  1. To implement a federated health data network in Europe.
  2. To enhance the supply and demand side to form a health data eco-system in compliance with robust privacy and ethics governance.
  3. To enable the development of new and augmented health services through available and expanded technologies, in the interest of improving health outcomes.

Central to EHDEN will be the standardisation of health data to the OMOP common data model and the adoption of analytical tools developed by the international Observational Health Data Sciences and Informatics (OHDSI) open science collaboration (www.ohdsi.org). A network of SMEs will be trained and certified to ensure high validity transformation of data to the common data model.

EHDEN’s aspirations are significant, aiming to harmonise 100 million, anonymised health records across multiple data sources, who can obtain funding from the EHDEN Harmonisation Fund to obtain support from certified/qualified SMEs through serial open calls. The project will support other IMI2 projects within a wider Big Data for Better Outcomes (BD4BO) programme, other IMI and non-IMI projects, and will collaborate strongly with other key stakeholders in Europe, such as the European Medicines Agency.

IMI2 EHDEN is supported by the Innovative Medicines Initiative Joint Undertaking (IMI-JU) under grant agreement number 806968

Acknowledgement

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Consortium

Erasmus Universitair Medisch Centrum Rotterdam

Netherlands

erasmusmc.nl
Synapse Research Management Partners S.L.

Spain

synapse-managers.com
The Chancellor, Masters and Scholars Of The University Of Oxford

United Kingdom

ox.ac.uk
Tartu Ulikool

Estonia

ut.ee
Universidade De Aveiro

Portugal

ua.pt
The Hyve Bv

Netherlands

thehyve.nl
Odysseus Data Services s.r.o.

Czech Republic

odysseusinc.com
Forum Europeen Des Patients

Luxembourg

eu-patient.eu
National Institute For Health And Care Excellence

United Kingdom

nice.org.uk
Stiftelsen WHO Collaborating Centre for International Drug Monitoring

Sweden

who.int
International Consortium for Health Outcome Measurement LTD

United Kingdom

ichom.org
Janssen Pharmaceutica

Belgium

janssen.com
Pfizer Limited

United Kingdom

pfizer.co.uk
AbbVie Inc

Germany

abbvie.com
Institut de Recherches Internationales Servier

France

servier.com
Sanofi Aventis GmbH

France

sanofi.com
Bayer AG

Germany

bayer.com
Eli Lilly

United Kingdom

lilly.com
IPSEN SAS

France

ipsen.com
AstraZeneca AB

Sweden

astrazeneca.com
Novartis Pharma AG

Switzerland

novartis.com
UCB BIOPHARMA SPRL

Belgium

ucb.com
Celgene Management SARL

Switzerland

celgene.com

Contact Us